Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Mazdutide and Retatrutide — mechanism, side effects, legal status, and pricing.
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Mazdutide
Retatrutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Mazdutide
Retatrutide
COA corpus from Disclosed Labs — independently tested batches only.
Mazdutide
6
COAs
99.7%
Avg purity
4
Labs
Retatrutide
413
COAs
99.7%
Avg purity
17
Labs
Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.
Phase 2 obesity trial (Jastreboff et al., NEJM 2023; PMID 37366315) demonstrated up to 24.2% body weight loss at 48 weeks at the 12 mg dose, exceeding both semaglutide and tirzepatide. A Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023; PMID 37385280) showed robust HbA1c and weight reductions vs. placebo and dulaglutide. A Phase 2a MASLD trial (Sanyal et al., Nat Med 2024; PMID 38858523) demonstrated significant reductions in hepatic steatosis driven by glucagon receptor activation. Phase 3 TRIUMPH trials are ongoing (Eli Lilly), with results expected 2025–2026. Retatrutide is NOT FDA-approved as of April 2026 — it remains investigational.
Mazdutide and Retatrutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs